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Introduction. Etiology of acute ischemic stroke (AIS) is known to signiﬁcantly inﬂuence management, prognosis, and risk of
recurrence. Objective. To determine if ischemic stroke subtype based on TOAST criteria inﬂuences mortality. Methods.W e
conducted an observational study of a consecutive cohort of patients presenting with AIS to a single tertiary academic center.
Results. The study population consisted of 500 patients who resided in the local county or the surrounding nine-county area. No
patients were lost to followup. Two hundred and sixty one (52.2%) were male, and the mean age at presentation was 73.7 years
(standard deviation, SD = 14.3). Subtypes were as follows: large artery atherosclerosis 97 (19.4%), cardioembolic 144 (28.8%),
small vessel disease 75 (15%), other causes 19 (3.8%), and unknown 165 (33%). One hundred and sixty patients died: 69 within
the ﬁrst 30 days, 27 within 31–90 days, 29 within 91–365 days, and 35 after 1 year. Low 90-, 180-, and 360-day survival was
seen in cardioembolic strokes (67.1%, 65.5%, and 58.2%, resp.), followed for cryptogenic strokes (78.0%, 75.3%, and 71.1%).
Interestingly, when looking into the cryptogenic category, those with insuﬃcient information to assign a stroke subtype had the
lowest survival estimate (57.7% at 90 days, 56.1% at 180 days, and 51.2% at 1 year). Conclusion. Cardioembolic ischemic stroke
subtype determined by TOAST criteria predicts long-term mortality, even after adjusting for age and stroke severity.
1.Introduction
Etiology of acute ischemic stroke (AIS) is known to sig-
niﬁcantly inﬂuence management, prognosis, and risk of
recurrence. Certain stroke subtypes are associated with
higher stroke severity at the time of presentation, which may
account for the higher mortality seen. In 1993 the TOAST
(TrailofORG10172inAcuteStrokeTreatment)investigators
described a classiﬁcation of AIS based on etiology, which is
now the most commonly used etiological classiﬁcation [1].
Comparison of clinical characteristics, functional outcomes,
and mortality rates for speciﬁc ischemic stroke mechanisms
may allow clinicians to identify those patients who are
at higher risk and to evaluate treatment strategies more
deﬁnitely.
We conducted an observational study of all patients
who presented to the emergency department (ED) with AIS
and determined if ischemic stroke subtype (ISS) inﬂuences
mortality even after correcting for stroke severity on initial
presentation.
2. Methods
This study was conducted at a tertiary care academic medical
center, with an annual ED census of approximately 75,000
visits. The medical records of all patients with a discharge
diagnosis of stroke or transient ischemic attack (TIA) or
diagnoses which could be mistaken for stroke or TIA were
screened (ICD-CM codes 433-437) between December 2001
and March 2004 to determine if the case met the criteria for2 Stroke Research and Treatment
diagnosis of ischemic stroke. This study was approved by the
authors’ institutional review board.
The medical records for all patients were reviewed, and
details of clinical history, demographic information, risk fac-
tor proﬁle, neurological examination, brain imaging studies,
and other diagnostic studies were abstracted. Followup was
updated for the ﬁnal data analysis using the date of the last
service or dismissal available from registration databases.
In addition, dates and causes of death were ascertained
from the State of Minnesota Electronic Death Certiﬁcate
Data; autopsy reports were also reviewed where available.
The National Institutes of Health Stroke Scale (NIHSS)
was calculated by physicians (LGS, RMG) certiﬁed in the
NIHSS, based on previously validated methods [2, 3]. The
scoring was derived from documentation of the neurological
examination performed by the neurologist on call at the
time of ED presentation. Stroke subtype was assigned to
every patient by two independent physicians based on review
of clinical history, neurological examination, and diagnostic
studies in accordance with criteria outlined in the TOAST
study. The TOAST classiﬁcation includes the following
categories: (1) large artery (LAD), (2) cardioembolic (CE),
(3) small vessel (SAD), (4) other determined cause, and (5)
cryptogenic.
Patients deﬁned as having large-artery atherosclerosis
had imaging showing greater than 50% stenosis or occlusion
of a major brain artery or branch cortical artery supplying
the region of brain aﬀected. A cardiac source of stroke was
assigned to patients with at least one of the following pre-
disposing factors (1) prosthetic valve, (2) signiﬁcant mitral
stenosis, (3) atrial ﬁbrillation or ﬂutter, (4) left atrial or ven-
tricular thrombus, (5) myocardial infarction <6 months
prior to stroke, (6) dilated cardiomyopathy, (7) akinetic/hy-
pokinetic left ventricular segment, (8) atrial myxoma, (9)
infective endocarditis, (10) sick-sinus syndrome, and (11)
congestive heart failure, in the absence of signiﬁcant ipsi-
lateral arterial stenosis. Patients with small vessel occlusion
had a clinical history of a classical lacunar syndrome with
either no evidence of infarction on neuroimaging or less
than 1.5cm infarct in the corresponding subcortical or
brainstem region. Patients with evidence of stroke of other
moreunusualetiologiessuchasvasculitisorhypercoagulable
states were classiﬁed as stroke of other determined cause.
Patients who did not meet the criteria for any of the above
categories were deﬁned as having cryptogenic stroke. This
category was comprised of 3 distinct groups of patients (a)
those that had more than one cause identiﬁed, (b) no cause
identiﬁed despite extensive investigations, and (c) insufﬁ-
cient information obtained to identify a cause.
3.StatisticalMethods
Theprimaryoutcomevariablewasmortalitywithin1year,as
estimated using the Kaplan-Meier method. For patients who
died within 1 year, the duration of followup was calculated
from the date of ED presentation to the date of death.
The duration of followup for all remaining patients was
censored at the date of last followup if within 1 year or at
366 days. Associations with survival were evaluated using
indicator variables in Cox proportional hazards models. The
associations were evaluated with and without adjusting for
sex, age, and NIHSS (ln (score + 0.5) of NIHSS which was
used in the model) and were summarized by calculating
risk ratios (RRs) and 95% conﬁdence intervals (CIs). All
calculated P values were two sided, and P values less
than 0.05 were considered statistically signiﬁcant. Statistical
analyses were performed using the SAS software package
(SAS Institute, Inc, Cary, NC).
4. Results
The initial study population consisted of all 681 consecutive
patients who presented to the ED with acute ischemic stroke.
Among these 681 patients, 19 denied research authoriza-
tion and were therefore excluded from further study in
accordance with Minnesota Statute 144.335. For purposes of
obtaining recent and consistent followup, this sample was
further limited to the 500 patients who resided in the local
county or the surrounding nine-county area at the time of
the ED visit. Hence, during the period of study 500 eligible
patients were identiﬁed. No patients were lost to followup.
Two hundred and sixty one (52.2%) were male, and the
mean age at presentation was 73.7 years (standard deviation,
SD = 14.3, range 18 to 101 years). Magnetic resonance imag-
ing or computed tomography (CT) of the brain was carried
out in all patients with 60% of patients having both imaging
modalities. Echocardiography was performed in 65% of
patients, 92% of which were transesophageal echocardiogra-
phy. 85% had vascular imaging with 65% of these having CT
angiogram or magnetic resonance angiogram.
All 500 patients were assigned a subtype, large artery ath-
erosclerosis 97 (19.4%), cardioembolic 144 (28.8%), small
vessel disease 75 (15%), other determined cause 19 (3.8%),
andunknown165(33%).Theunknowncategorywasfurther
subdivided into: more than one cause identiﬁed 37 (7.4%),
no cause identiﬁed 63 (12.6%), and those with insufﬁcient
investigations performed to identify a cause 65 (13.0%).
Detailed information of the demographic characteristics by
ISS is presented in Table 1.
One hundred and sixty patients died: 69 within the
ﬁrst 30 days, 27 within 31–90 days, 29 within 91–365 days,
and 35 after 1 year. The estimated survival (±standard
error) at 90 days, 180 days, and 1 year was 80.1% ± 1.8%,
77.5% ± 1.9%, and 73.5% ± 2.0%, respectively. Among the
patients alive at last followup, the median followup was 1.8
years (interquartile range, 1.1–2.6 years). The lower 90-,
180-, and 360-day survival was seen in cardioembolic strokes
(67.1%, 65.5%, and 58.2%, resp.), followed for cryptogenic
strokes (78.0%, 75.3%, and 71.1%). Interestingly, when
looking into the cryptogenic category, those with insuﬃcient
information to assign a stroke subtype had the lowest
survival estimate (57.7% at 90 days, 56.1% at 180 days and
51.2% at 1 year). The survival estimates (±standard error)
b yT O A S Tc a t e g o r ya r ep r e s e n t e di nTable 2 and Figure 1.
In order to calculate risk ratios (RR) for comparing the
survival within the ﬁrst year across the TOAST categories, we
built 3 models to adjust for diﬀerent factors. These models
are summarized in Table 3. Using the SAD group as theStroke Research and Treatment 3
Table 1: Summary of patient characteristics by TOAST classiﬁcation.
Large vessel
(N = 97)
Cardioembolic
(N = 144)
Small vessel
(N = 75)
Other
(N = 19)
Multiple
causes
(N = 37)
No cause
identiﬁed
(N = 63)
Insuﬃcient info
(N = 65)
Male gender 67 (69.1%) 66 (45.8%) 39 (52%) 10 (52.6%) 21 (56.8%) 32 (50.8%) 26 (40%)
Age
Mean (SD) 70.7 (12.22) 78.4 (11.81) 72.6 (13.50) 50.7 (19.71) 73.8 (9.90) 66.6 (16.78) 82.3 (8.32)
Range 39–91 41–101 44–94 18–82 39–90 25–89 59–98
NIHSS
Mean (SD) 7.0 (6.40) 10.1 (9.06) 3.8 (2.71) 5.7 (5.77) 8.1 (8.92) 6.3 (7.14) 13.4 (11.26)
Median 4.0 7.0 3.0 5.0 4.0 4.0 9.5
Q1, Q3 3.0, 10.0 3.0, 15.0 2.0, 5.0 1.0, 8.0 2.0, 8.0 1.0, 8.0 4.0, 20.0
Prior MI 14 (14.4%) 16 (11.1%) 11 (14.7%) 1 (5.3%) 13 (35.1%) 8 (12.7%) 9 (13.8%)
CHF 7 (7.2%) 46 (31.9%) 6 (8%) 0 (0%) 12 (32.4%) 2 (3.2%) 10 (15.4%)
Coronary artery
disease 25 (25.8%) 40 (27.8%) 19 (25.3%) 3 (15.8%) 18 (48.6%) 13 (20.6%) 16 (24.6%)
Atrial
ﬁbrillation 8 (8.2%) 89 (61.8%) 3 (4%) 2 (10.5%) 15 (40.5%) 3 (4.8%) 6 (9.2%)
Prior stroke 22 (22.7%) 35 (24.3%) 13 (17.3%) 2 (10.5%) 11 (29.7%) 15 (23.8%) 19 (29.2%)
Prior TIA 19 (19.6%) 20 (13.9%) 14 (18.7%) 0 (0%) 8 (21.6%) 9 (14.3%) 12 (18.5%)
HTN 75 (77.3%) 110 (76.4%) 61 (81.3%) 8 (42.1%) 32 (86.5%) 48 (76.2%) 51 (78.5%)
Hyperlipidemia 58 (59.8%) 56 (38.9%) 43 (57.3%) 3 (15.8%) 18 (48.6%) 31 (49.2%) 23 (35.4%)
Diabetes 28 (%) 35 (%) 30 (%) 2 (%) 9 (%) 18 (%) 13 (%)
Smoker
Never 32 (33%) 79 (54.9%) 44 (58.7%) 10 (52.6%) 20 (54.1%) 23 (36.5%) 30 (46.2%)
Active 24 (24.7%) 14 (9.7%) 13 (17.3%) 4 (21.1%) 2 (5.4%) 16 (25.4%) 6 (9.2%)
Former 40 (41.2%) 44 (30.6%) 17 (22.7%) 5 (26.3%) 12 (32.4%) 23 (36.5%) 25 (38.5%)
Table 2: Survival estimates within the ﬁrst year.
TOAST N Events Survival at 90
days (SE)
Survival at 180
days (SE)
Survival at 360
days (SE)
Large artery 97 16 87.1% (0.04) 82.4% (0.04) 82.4% (0.04)
Cardioembolic 144 57 67.1% (0.04) 65.5% (0.04) 58.2% (0.04)
Small vessels 75 4 98.6% (0.01) 97.1% (0.02) 94.2% (0.03)
Other 19 3 89.5% (0.07) 84.2% (0.08) 84.2% (0.08)
Cryptogenic 165 45 78.0% (0.03) 75.3% (0.03) 71.1% (0.04)
More than one cause 37 7 85.5% (0.06) 82.3% (0.07) 79.2% (0.07)
No cause 63 7 94.8% (0.03) 91.2% (0.04) 87.4% (0.05)
Insuﬃcient info 65 31 57.7% (0.06) 56.1% (0.06) 51.2% (0.06)
reference, patients with LAD, CE, or cryptogenic strokes
had signiﬁcantly poorer survival (Model 1). This association
w a ss t i l lo b s e r v e da f t e ra d j u s t i n gf o ra g ea n dg e n d e r( M o d e l
2 ) .H o w e v e r ,a f t e ra d j u s t i n gf o ra g ea n dN I H S S( M o d e l3 ) ,
only the diﬀerence between CE and SAD attained statistical
signiﬁcance, with a RR 3.4 (95% CI 1.2–9.6).
Most deaths (60%) in our cohort were attributable to
the acute stroke itself, conﬁrming the results of others [4].
Other causes were respiratory distress/pneumonia (15%),
cardiovascular (myocardial infarction and congestive heart
failure) (7%), and renal failure (7%).
We are unable to comment on whether there was a
diﬀerence in tPA treatment or revascularization between
subtypes as we did not have patient-speciﬁc data on which
patients in this dataset as to who received t-PA by subtype.
Overall,thenumberofpatientswhoreceivedt-PAduringthe
study period was small and thus would likely have little eﬀect
on outcomes by subtype.
5. Discussion
Cardioembolic stroke is known to have the worst progno-
sis amongst ischemic stroke subtypes, and this has been
reported in the literature [4, 5]. However, in contrast to the
current study, these studies have failed to show CE stroke as
an independent predictor of mortality. Bang et al. showed4 Stroke Research and Treatment
Table 3: Risk ratios of mortality.
Factors Model 1 Model 2 Model 3
included RR (95% CI) RR (95% CI) RR (95% CI)
P value P value P value
TOAST
LAD 3.5 (1.2–10.4) P = 0.027 4.0 (1.3–11.9) P = 0.014 2.1 (0.7–6.4) P = 0.18
CE 9.4 (3.4–25.9) P<0.001 7.8 (2.8–21.4) P<0.001 3.4 (1.2–9.6) P = 0.020
SAD Reference Reference Reference Reference
Other 3.1 (0.7–13.9) P = 0.14 9.0 (2.0–41.3) P = 0.005 4.7 (1.0–21.6) P = 0.05
Cryptogenic 18.9 (2.2–17.1) P<0.001 5.9 (2.1–16.3) P<0.001 2.5 (0.9–7.0) P = 0.094
Female n/a 0.9 (0.6–1.3) P = 0.48 n/a
Age∗ n/a 1.8 (1.5–2.2) P<0.001 1.6 (1.3–1.9) P<0.001
Ln(NIHSS)∗∗ n/a n/a 3.6 (2.8–4.7) P<0.001
∗Risk ratio per 10 year increase in age.
∗∗Risk per a doubling in NIHSS score.
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Figure 1: Survival estimates by TOAST classiﬁcation.
that ischemic stroke subtype was a signiﬁcant predictor of
recurrent stroke after adjusting for potential confounders
but did not ﬁnd that it was an independent predictor of
poor prognosis [6]. Sprigg et al. reported in their evaluation
of the TAIST (Tinzaparin in Acute Ischemic Stroke Trial)
that patients with small vessel occlusion had better outcome
as compared to patients with large artery atherosclerosis or
cardioembolic stroke [7]. Internationally there seems to be a
similar trend. Recently Winter et al. reported from Marburg
that patients with cardioembolic stroke had more severe
clinical deﬁcits on presentation, and a worse outcome, than
the other stroke subtypes [8]. A community-based study
from Brazil also reported the highest case fatality rate in
strokes of undetermined etiology followed by cardioembolic
stroke and large vessel atherothrombosis [9]. Lavados and
colleagues from Chile reported a similar higher mortality for
cardioembolic stroke when compared to small vessel disease
[10].
We have demonstrated an association between CE stroke
and increased mortality, independent of age, gender, and
NIHSS. It would appear likely that cardiac and other comor-
bidities most likely explain this ﬁnding. Cardiac conditions
that predispose to stroke (such as extensive acute myocardial
infarction, chronic myocardial injury with left ventricular
aneurysm formation, valvular and nonvalvular atrial ﬁbril-
lation) are themselves associated with increased mortality.
It is not unexpected that such patients would carry a partic-
ularly poor prognosis after acute ischemic stroke. Similarly,
conditions such as diabetes that may underlie such heart
diseases may also increase risk for poor outcome following
stroke.
The ﬁndings of this study clearly identify patients
presenting with CE stroke as a particularly high risk group.
How best to optimize therapy and ameliorate that risk for
these patients, however, is uncertain. For example, whether
strokesubtypemayinﬂuenceeﬃcacyofestablishedtherapies
such as thrombolytic therapy is unknown. It is probably
reasonable to assume that embolic material in CE stroke is
predominantly thrombus laden (rather than composed of
plaque debris, as may pertain in aortic and carotid artery
disease). If this assumption is indeed correct, then one
could hypothesize that patients with CE stroke may be a
subgroup that ought to derive greater beneﬁt from timely
administration of thrombolysis and may conceivably beneﬁt
from thrombolysis over an extended time window beyond
the conventional three hours from symptom onset. Greater
vigilance in respect of blood pressure control during the
acute phase of stroke may be warranted. Heightened aware-
ness of poor prognosis among these patients may also lead to
more aggressive treatment of coexisting cardiac disorders.
6. Conclusion
Cardioembolic ischemic stroke subtype determined by
TOAST criteria predicts long-term mortality, even after
adjustingforageandstrokeseverity.Furtherstudiestodeﬁne
the precise nature of this increased risk will be requiredStroke Research and Treatment 5
to guide the development of strategies which may improve
outcome in this setting.
Acknowledgments
Dr. L. G. Stead was supported through a Mayo Foundation
Emergency Medicine Research Career Development Award
during the period of this research. This paper was made
possible by Grant no. 1 UL1 RR024150 from the National
Center for Research Resources (NCRR), a component of the
National Institutes of Health (NIH), and the NIH Roadmap
for Medical Research. The contents of this paper are solely
the responsibility of the authors and do not necessarily
represent the oﬃcial view of NCRR or NIH. Information on
NCRR is available at http://www.ncrr.nih.gov/. Information
on Reengineering the Clinical Research Enterprise can be
obtained from http://nihroadmap.nih.gov/.
References
[1] H. P. Adams Jr., B. H. Bendixen, L. J. Kappelle et al.,
“Classiﬁcationofsubtypeofacuteischemicstroke.Deﬁnitions
for use in a multicenter clinical trial. Toast. Trial of org 10172
in acute stroke treatment,” Stroke, vol. 24, pp. 35–41, 1993.
[2] S. E. Kasner, J. A. Chalela, J. M. Luciano et al., “Reliability and
validity of estimating the NIH stroke scale score from medical
records,” Stroke, vol. 30, no. 8, pp. 1534–1537, 1999.
[3] L. S. Williams, E. Y. Yilmaz, and A. M. Lopez-Yunez,
“Retrospective assessment of initial stroke severity with the
NIH stroke scale,” Stroke, vol. 31, no. 4, pp. 858–862, 2000.
[4] G. de Jong, L. Van Raak, F. Kessels, and J. Lodder, “Stroke
subtypeandmortality:afollow-upstudyin998patientswitha
ﬁrst cerebral infarct,” Journal of Clinical Epidemiology, vol. 56,
no. 3, pp. 262–268, 2003.
[5] M. Murat Sumer and O. Erturk, “Ischemic stroke subtypes:
risk factors, functional outcome and recurrence,” Neurological
Sciences, vol. 22, no. 6, pp. 449–454, 2002.
[6] O. Y. Bang, P. H. Lee, S. Y. Joo, J. S. Lee, I. S. Joo, and
K. Huh, “Frequency and mechanisms of stroke recurrence
after cryptogenic stroke,” Annals of Neurology, vol. 54, no. 2,
pp. 227–234, 2003.
[ 7 ]N .S p r i g g ,L .J .G r a y ,P .M .W .B a t he ta l . ,“ E a r l yr e c o v e r y
andfunctionaloutcomearerelatedwithcausalstrokesubtype:
data from the Tinzaparin in acute ischemic stroke trial,”
Journal of Stroke and Cerebrovascular Diseases,v o l .1 6 ,n o .4 ,
pp. 180–184, 2007.
[8] Y. Winter, C. Wolfram, M. Schaeg et al., “Evaluation of costs
and outcome in cardioembolic stroke or TIA,” Journal of
Neurology, vol. 256, no. 6, pp. 954–963, 2009.
[9] N. L. Cabral, A. R.R. Gonc ¸alves, A. L. Longo et al., “Incidence
of stroke subtypes, prognosis and prevalence of risk factors in
Joinville, Brazil: a 2 year community based study,” Journal of
Neurology,NeurosurgeryandPsychiatry,vol.80,no.7,pp.755–
761, 2009.
[10] P. M. Lavados, C. Sacks, L. Prina et al., “Incidence, case-
fatality rate, and prognosis of ischaemic stroke subtypes in a
predominantlyHispanic-MestizopopulationinIquique,Chile
(PISCIS project): a community-based incidence study,” The
Lancet Neurology, vol. 6, no. 2, pp. 140–148, 2007.